Time ( Supplemental figure S2. Extracted ion chromatograms for MHLPSPTDSNFpYR and MHLPpSPTDSNFYR using Xcalibur software (ThermoFisher, San Jose, CA). These peptides are chromatographically separated from each other and sequence specific ions used to determine which peak corresponds to pY and pS peptide.
Supplemental figure S3. Standard curves for phosphopeptides spiked at increasing concentrations into BSA digest (five technical replicates). Normalized pSRM signal is calculated by dividing the phosphopeptide peak area (sum of 3-4 transitions) by the BSA reference peptide peak area (sum of 3 transitions). Color denotes different reference peptides used for normalization.
HLVDEPQNLIK LVNELTEFAK KVPQVSTPTLVEVSR +3 KVPQVSTPTLVEVSR +2
 all peptides SLHTLFGDELCK YICDNQDTISSK Supplemental figure S10. Figure S11 . Human epidermal growth factor receptor (hEGFR) amino acid sequence. Normalizing and phosphorylated peptides are highlighted in different colors. The nonphosphorylated peptides that were chosen to be used as normalizing peptides are located in the extracellular domain (IPLENLQIIR, NLQEILHGAVR and EISDGDVIISGNK), juxtamembrane (GLWIPEGEK) and tyrosine kinase domain (ITDFGLAK). Two phosphopeptides that we monitored are located in the tyrosine kinase domain (MHLPpSPTDSNFYR and MHLPSPTDSNFpYR) The other four phosphopeptides (pY and pS) that were monitored are located in the cytoplasmic domain (RPAGSVQNPVpYHNQPLNPAPSR, GSHQIpSLDNPDYQQDFFPK, GSHQISLDNPDpYQQDFFPK and GSTAENAEpYLR). Supplemental figure S12. The retention time for normalizing peptides ranged across the peptide elution retention time. Retention time plots for all internal nonphosphorylated reference peptides (top) and stable-isotope labeled pY peptides, Y998 -MHLPSPTDSNFpYR, Y1110 -RPAGSVQNPVpYHNQPLNPAPSR, Y1172 -GSHQISLDNPDpYQQDFFPK, and Y1197 -GSTAENAEpYLR) (bottom). Retention time plots were generated from biological replicate 3, technical replicate 3. The underlined amino acid indicates which amino acid was stable isotope labeled. Supplemental table S13. EGFR phosphorylated and nonphosphorylated peptides and transitions selected for LC-pSRM-MS. 1 Peptides marked with ^ are isotopically labeled, the ^ indicates which amino acid was stable isotope labeled. Supplemental figure S14. Median CV plots for peptide MHLPSPTDSNFpYR. The CV's were calculated by the technical replicate analysis on a per treatment and internal reference/stable isotope labeled peptide basis. (A-C) All data (three technical replicates for each treatment) was used to calculate median CV's for biological replicate 1 (A), 2 (B) and 3 (C). The black dashed line represents 15% CV, and the red dashed line represents 30% CV. Data was not detected in proliferating, co-treated gefitinib followed by EGF samples. Supplemental figure S20 . Time vs. ion injection time for five internal reference peptides and a stable isotope labeled peptide (GSTAENAEpYLR) for EGF treated samples (biological replicate 3). The maximum allowable ion injection time in these experiments is 100ms. These data show the ion injection time for technical replicate 1 was drastically different than both technical replicates 2 and 3, i.e., technical replicate 1 always required a longer ion injection time for the same sample, suggesting the instrument was behaving differently during the EGF treated technical replicate 1 run. These data indicate the reason why large CV values for EGF treated biological replicate 3 was observed. Supplemental figure S21 . Extraction ion chromatograms (time vs. relative abundance (%)) for five internal reference peptides and a stable isotope labeled peptide (GSTAENAEpYLR) for EGF treated samples (biological replicate 3). These data show that the relative abundance (%) for technical replicate 1 is drastically different than both technical replicates 2 and 3, i.e., technical replicate 1 has a low intensity for the same sample, suggesting the instrument was behaving significantly different during the EGF treated biological replicate 3 (technical replicate 1 run). These data indicate the reason why large CV values for EGF treated biological replicate 3 was observed. Supplemental figure S22 . Time vs. ion injection time for five internal reference peptides and a stable isotope labeled peptide (GSTAENAEpYLR) for proliferating samples (biological replicate 3). The maximum allowable ion injection time in these experiments is 100ms. These data show the ion injection time for technical replicate 1 was similar to both technical replicates 2 and 3, unlike supplemental figure S17. Supplemental figure S23 . Extraction ion chromatograms (time vs. relative abundance (%)) for five internal reference peptides and a stable isotope labeled peptide (GSTAENAEpYLR) for proliferating samples (biological replicate 3). These data show that the relative abundance (%) for technical replicate 1 was similar to both technical replicates 2 and 3. The XICs for technical replicate 1 were similar to both technical replicates 2 and 3, unlike supplemental figure S18. figure S24 . Normalized pSRM plots (MHLPSPTDSNFpYR) for each internal reference peptide and SID peptide for each sample type (P -proliferating, E -EGF stimulated, G + E -Gefitinib treatment followed by EGF and C + E -Cetuximab treatment followed by EGF). Data from biological replicate 1 (biological replicate 2 and 3 generate similar results), 3 technical replicates. Data was "not detected" for P and G + E samples. figure S25 . Normalized pSRM plots (RPAGSVQNPVpYHNQPLNPAPSR) for each internal reference peptide and SID peptide for each sample type (P -proliferating, E -EGF stimulated, G + E -Gefitinib treatment followed by EGF and C+ E -Cetuximab treatment followed by EGF). Data from biological replicate 1 (biological replicate 2 and 3 generate similar results), 3 technical replicates.
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